<DOC>
	<DOCNO>NCT00699517</DOCNO>
	<brief_summary>The primary objective study compare progression-free survival ( PFS ) 2 treatment arm The secondary objective study : - To compare overall survival 2 treatment arm - To compare objective response rate 2 treatment arm - To assess safety profile AVE8062 ( combination background cisplatin therapy ) - To assess pharmacokinetics AVE8062 main metabolite , RPR258063 , use population approach , patient enrol select center .</brief_summary>
	<brief_title>A Study AVE8062 Advanced-stage Soft Tissue Sarcoma After Failure Anthracycline Ifosfamide Chemotherapies</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Inclusion criterion : Histologically proven soft tissue sarcoma Unresectable locoregional recurrent metastatic soft tissue sarcoma Failure previous anthracyclinebased regimen administer recommend dose prior ifosfamide therapy Exclusion criterion : Less 3 week elapse prior treatment radiotherapy , surgery , chemotherapy time randomization Brain metastases carcinomatous leptomeningitis Uncontrolled hypertension Known platinum hypersensitivity The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>tubulin modulator</keyword>
	<keyword>endothelium</keyword>
	<keyword>combretastatin</keyword>
	<keyword>cisplatin</keyword>
</DOC>